



Keenan[®]

Keenan Pharmacy Services
San Joaquin Valley Insurance Authority
(SJVIA)
Consultants Report: Plan Year 2023

SJVIA- EmpiRx Health – 2023 Annual Highlights

- SJVIA's total plan cost increased in 2023 by 11% to \$25,594,410
 - Tulare: \$10,951,498 in Plan Cost
 - Fresno: \$14,642,911 in Plan Cost
 - The increase in plan spend can be attributed to an increase in Total Rx count.
- Specialty claims plan cost decreased in 2023
 - 2023: \$10,454,477 (2022: \$10,526,068)
 - 2,724 Scripts filled in 2023 (2022: 2,416)
 - Tulare: 983
 - Fresno: 1,741
- Variable Copay Assistance (VCAP) Savings (May 2023 – February 2024)
 - SJVIA Total Savings: \$1,188,766
 - Tulare: \$449,175
 - Fresno: \$739,591
- Rebates:
 - Q1-2023 net rebate amount is \$1,154,820
 - Q2-2023 net rebate amount is \$1,212,184
 - Q3-2023 net rebate amount is \$1,186,675
 - Q4-2023 net rebate amount is \$1,220,630
- Clinical Savings:
 - SJVIA Tulare: Jan-Nov 2023, \$2,207,036
 - SJVIA Fresno: Jan-Nov 2023, \$3,037,905

KPS Audit

KPS conducts a yearly financial audit of EmpiRx clinical savings, Average Wholesale Price (AWP) discounts and rebate performance against the client's aggregate contractual guarantees.



Top Clinical Cost Drivers by Drug (Q1 – Q4 2023)

- OZEMPIC (ANTI-DIABETICS)
 - 2023 ingredient costs: \$1,926,539.77
 - 324 Utilizers
- HUMIRA PEN (ANALGESICS - ANTI-INFLAMMATORY)
 - 2023 Q1-Q4 ingredient costs: \$1,396,123.48
 - 23 Utilizers
- WEGOVY (ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS)
 - 2023 Q1-Q4 ingredient costs: \$1,080,538.77
 - 235 Utilizers
- DUPIXENT (DERMATOLOGICALS)
 - 2023 Q1-Q4 ingredient costs: \$915,953.26
 - 36 Utilizers
- TRULICITY (ANTI-DIABETICS)
 - 2023 Q1-Q4 ingredient costs: \$830,325.09
 - 128 Utilizers
- JARDIANCE (ANTI-DIABETICS)
 - 2023 Q1-Q4 ingredient costs: \$590,996.57
 - 146 Utilizers
- EMPAVELI (HEMATOLOGICAL AGENTS - MISC)
 - 2023 Q1-Q4 ingredient costs: \$492,496.16
 - 1 Utilizers
- FARXIGA (ANTI-DIABETICS)
 - 2023 Q1-Q4 ingredient costs: \$472,250.37
 - 108 Utilizers
- TREMFYA (DERMATOLOGICALS)
 - 2023 Q1-Q4 ingredient costs: \$452,800.84
 - 10 Utilizers
- RYBELSUS (ANTI-DIABETICS)
 - 2023 Q1-Q4 ingredient costs: \$451,446.42
 - 75 Utilizers
- Note: Specialty medications require a prior authorization before they can be filled.



New Medications Available in the Market

- **Update on Zepbound**

- Zepbound was added to EmpiRx Formulary on 4/1/2024 as a non-preferred brand (Tier 3)
 - Prior to 4/1/24: Zepbound was on the “New To Market” list while awaiting formulary assignment by the EmpiRx Health P&T Committee.
 - During this time, Clinical Reviews could still be opened by members and their doctors, with coverage granted on a case-by-case basis
 - From 11/1/2023 – 3/31/2024 There were 61 members that attempted to fill a prescription for Zepbound
 - 6 members have been clinically approved
 - 54 members did not meet clinical criteria
 - 1 prior authorization was withdrawn

- **Update on Biosimilars for Humira**

- No current utilizers of Humira biosimilars for SJVIA yet
 - There are currently 16 members on Humira and EmpiRx has been continuing to make outreach to providers to educate them and recommend switching to one of the two preferred BioSimilar when clinically appropriate

- **New Drug Approved**

- **Rezdiffra (Resmetirom):** First medication approved for treatment of NASH. It is a thyroid hormone receptor-beta (THR- β) agonist.
- Approved for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis, in conjunction with diet and exercise
 - NASH is the most severe form of nonalcoholic fatty liver disease (NAFLD) and is characterized by an abnormal accumulation of fat in the liver, affecting 1.5-6.5% of US adults.
- Rezdiffra is dosed orally once daily, using weight-based dosing ranging from 80mg to 100mg orally daily.
 - The annual wholesale acquisition cost (WAC) is \$48,058.
- The EmpiRx Health P&T Committee will review in May 2024 for formulary placement and clinical edits to ensure safe & appropriate use and will be considered a New to Market medication until then.
 - All New to Market medications are excluded until they undergo a review for placement onto formulary and clinical programs by the Pharmacy & Therapeutics (P&T) Committee.
 - Rezdiffra will be considered a specialty medications and would require a clinical review if added to the formulary
 - Utilization is expected to be minimal for SJVIA.